Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

670P - Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-Like T cell engager BI 764532 in patients (pts) with DLL3-positive tumors: Updated data

Date

14 Sep 2024

Session

Poster session 01

Topics

Tumour Site

Neuroendocrine Neoplasms

Presenters

Martin Wermke

Citation

Annals of Oncology (2024) 35 (suppl_2): S482-S535. 10.1016/annonc/annonc1589

Authors

M. Wermke1, V. Gambardella2, Y. Kuboki3, E. Felip4, M.F. Sanmamed5, O. Alese6, C.M. Sayehli7, E. Arriola Aperribay8, J. Wolf9, L. Villaruz10, M. Studeny11, M. Bouzaggou12, X. Fang13, D. Morgensztern14

Author affiliations

  • 1 Tu Dresden University Of Technology, NCT/UCC Early Clinical Trial Unit, 01307 - Dresden/DE
  • 2 Department Of Medical Oncology, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia, Valencia/ES
  • 3 Department Of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa/JP
  • 4 Department Of Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona/ES
  • 5 Department Of Oncology, Clínica Universidad de Navarra, Pamplona/ES
  • 6 Department Of Hematology And Medical Oncology, Winship Cancer Institute of Emory University, Atlanta/US
  • 7 Interdisciplinary Study Center With Ectu, Medical Clinic and Polyclinic II of the University Hospital, Wuerzburg/DE
  • 8 Department Of Medical Oncology, Hospital del Mar-CIBERONC (Centro de Investigación Biomédica en Red de Oncología); Cancer Research Program, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona/ES
  • 9 Center For Integrated Oncology, University Hospital of Cologne, Cologne/DE
  • 10 Division Of Hematology/oncology, UPMC Hillman Cancer Center, Pittsburgh/US
  • 11 Medicine, Boehringer Ingelheim International GmbH, Ingelheim am Rhein/DE
  • 12 Clinical Development And Operations, Boehringer Ingelheim France S.A.S., Reims/FR
  • 13 Global Biostatistics & Data Sciences, Boehringer Ingelheim (China) Investment Co., Ltd., Shanghai/CN
  • 14 Division Of Oncology, Washington University School of Medicine, St. Louis/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 670P

Background

DLL3 is expressed on many cancers, including small-cell lung cancer (SCLC), extrapulmonary neuroendocrine carcinomas (epNECs), and large cell neuroendocrine carcinoma of the lung (LCNEC). BI 764532 is a DLL3/CD3 IgG-like T cell engager that initiates T cell-mediated immune responses against DLL3+ tumors. NCT04429087 is a Phase I trial of BI 764532 in pts with DLL3+ SCLC, epNECs or LCNEC.

Methods

Escalating doses of BI 764532 were given IV in 4 regimens: RA (fixed dose q3w); RB1 (fixed dose qw); RB2 and RB3 (step-in dose, then target dose). Treatment (Tx) continued until progression, unacceptable toxicity, other withdrawal criteria, or for 36 months (mos) maximum. Primary objective: determine MTD and/or RDE of BI 764532. Other objectives: safety; tolerability; PK/PD; preliminary efficacy (investigator-assessed; RECIST 1.1).

Results

As of Feb 21, 2024, 168 pts had ≥1 dose of BI 764532 (RA: n=24; RB1: n=10; RB2: n=79; RB3: n=55). Median age: 61 yrs (range 32–81); ECOG PS 0/1/missing: 27/67/5%; prior PD1/PD-L1 Tx: 51%; ≥2 prior lines of Tx: 72%. SCLC/epNEC/LCNEC: 49/42/8%. 6 pts experienced DLTs during the MTD evaluation period (all on RB2): G4 CRS; G3 CRS; G5 ICANS; G3 ICANS; G3 nervous system disorder; G2 infusion-related reaction). MTD was not reached. TRAEs (any/G3+): overall 88/24%; RA 79/21%; RB1 60/20%; RB2 96/34%; RB3 86/11%. Most common TRAEs were (any/G3+): CRS (57/3%); dysgeusia (23/0%); pyrexia (21/0%); asthenia (20/1%). With RB2/RB3, most CRS and neurological events occurred early, and were reversible. Unconfirmed tumor response data are shown below. Efficacy was highest with RB2/RB3 where all pts received target doses of ≥90 μg/kg. Overall, median DoR (95% CI): 8.5 mos (6.2—NR); estimated 6-mo DoR: 70%. 23/38 responding pts are still on Tx. Median PFS (95% CI): 1.5 mos (1.4-2.4); estimated 6-mo PFS: 20%.

Conclusions

BI 764532 showed clinically manageable tolerability and promising efficacy in SCLC, epNEC and LCNEC. Table: 670P

SCLC ORR/DCR, % n epNEC ORR/DCR, % n LCNEC ORR/DCR, % n All ORR/DCR, % n
RA 7/20 15 14/29 7 0/50 2 8/25 24
RB1 0/0 4 0/20 5 0/0 1 0/10 10
RB2 22/44 41 22/41 32 83/100 6 27/47 79
RB3† 20/40 20 31/50 26 50/75 4 29/49 51
Total 18/36 80 23/41 70 54/77 13 23/42 164*

*Assessable pts started Tx ≥7 wks prior to data cut-off; †tumor type missing in one patient

Clinical trial identification

NCT04429087.

Editorial acknowledgement

Medical writing support for the development of this abstract was provided by Lynn Pritchard, DPhil, of Ashfield MedComms.

Legal entity responsible for the study

Boehringer Ingelheim.

Funding

Boehringer Ingelheim.

Disclosure

M. Wermke: Financial Interests, Personal, Other, Honoraria: Amgen, Boehringer Ingelheim, Eli Lilly, GWT, Janssen, Merck Serono, Novartis, Synlab; Financial Interests, Personal, Other, Travel/accommodation/expenses: Amgen, AstraZeneca, Bristol Myers Squibb, GEMoaB, Immatics, Merck Serono, Pfizer, Sanofi/Aventis; Financial Interests, Personal and Institutional, Research Funding: Roche; Financial Interests, Personal, Speaker, Consultant, Advisor: Amgen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, ImCheck Therapeutics, Immatics, ISA Pharmaceuticals, Novartis. V. Gambardella: Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Institutional, Funding: Genentech, Merck Serono, Roche, Beigen, Bayer, Servier, Lilly, Novartis, Takeda, Astelas, Fibrogen, Amcure, Natera, Sierra Oncology, AstraZeneca, Medimmune, BMS, MSD; Financial Interests, Personal, Research Funding: Bayer, Boehringer Ingelheim, Roche. Y. Kuboki: Financial Interests, Personal, Advisory Board: Amgen, Boehringer Ingelheim, Takeda, Incyte, Abbie; Financial Interests, Personal, Other, Honoraria: Eli Lilly Japan, Taiho Pharmaceutical, Takeda; Financial Interests, Institutional, Research Funding: AbbVie, Amgen, Astellas Pharma, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Genmab, Incyte, Ono Pharmaceutical, Taiho Pharmaceutica, Takeda, AstraZeneca, Merck, Novartis, Hengrui. E. Felip: Financial Interests, Personal, Advisory Role: AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Genmab, Gilead, GSK, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Peptomyc, Pfizer, Regeneron, Sanofi, Takeda, Turning Point, Daiichi Sankyo; Financial Interests, Personal, Other, independent member of the board: Grifols; Financial Interests, Personal, Speaker’s Bureau: Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, F. Hoffmann-La Roche, Genentech, Janssen, Medical Trends, Medscape, Merck Serono, Merck Sharp & Dohme, Peervoice, Pfizer, Sanofi, Takeda, Touch Oncology. M.F. Sanmamed: Non-Financial Interests, Personal and Institutional, Research Funding: Roche; Financial Interests, Personal, Speaker, Consultant, Advisor: Numab; Financial Interests, Personal, Royalties: MSD. O. Alese: Financial Interests, Personal, Advisory Board: Ipsen Pharmaceuticals, Aadi Bioscience, Taiho, Pfizer, Seagen Inc., Bristol Myers Squibb, AstraZeneca, Exelixis, Takeda; Financial Interests, Institutional, Research Grant: Taiho Oncology, Ipsen Pharmaceuticals, GSK, Bristol Myers Squibb, Suzhou Transcenta Therapeutics Co. Ltd., Boehringer Ingelheim, Cue Biopharma, Inc., Merck, Inhibitex Inc, Arcus Biosciences Inc. C.M. Sayehli: Financial Interests, Institutional, Coordinating PI: Boehringer Ingelheim; Financial Interests, Personal, Other, Travel/accommodation/expenses: Boehringer Ingelheim, Catalym, Eli Lilly, Ipsen Pharma. E. Arriola Aperribay: Financial Interests, Personal, Other, Honoraria: Takeda, Lilly, Roche, Boehringer Ingelheim, Bristol Myers Squibb, AstraZeneca; Financial Interests, Personal, Other, Travel/accommodation/expenses: Takeda, Roche, MSD, AstraZeneca; Financial Interests, Institutional, Research Funding: AstraZeneca; Financial Interests, Personal, Speaker, Consultant, Advisor: Takeda, Lilly, Roche, MSD, Boehringer Ingelheim, BMS, AstraZeneca. J. Wolf: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Bayer, Blueprint, BMS, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Ignyta, Janssen, Lilly, Loxo, Merck, Mirati, MSD (Merck Sharp & Dohme), Novartis, Nuvalent, Pfizer, Roche, Seattle Genetic, Takeda, Turning Point; Financial Interests, Institutional, Research Funding: BMS, Janssen, Novartis, Pfizer, AstraZeneca. L. Villaruz: Financial Interests, Personal, Advisory Board: Sanofi, Gilead, Johnson and Johnson, Daiichi Sankyo, AstraZeneca; Financial Interests, Personal, Advisory Role: EMD Serono. M. Studeny, M. Bouzaggou, X. Fang: Financial Interests, Personal, Full or part-time Employment: Boehringer Ingelheim. D. Morgensztern: Financial Interests, Personal, Advisory Board: AbbVie, Eli Lilly, Arcus, Mirati; Financial Interests, Personal, Advisory Role: Arcus; Financial Interests, Personal, Principal Investigator: AbbVie, Arcus, Merck, Novartis, Pfizer, Bristol Myers Squibb, Incyte, Surface, Amgen, Genprex, Boehringer Ingelheim, NeoImmunotech, Apollomics.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.